Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
4.670
-0.330 (-6.60%)
At close: Jun 26, 2026, 4:00 PM EDT
4.800
+0.130 (2.78%)
After-hours: Jun 26, 2026, 7:47 PM EDT
Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Nadav Kidron |
Contact Details
Address: 1185 Avenue of the Americas, Third Floor New York, New York 10036 United States | |
| Phone | 844 967 2633 |
| Website | oramed.com |
Stock Details
| Ticker Symbol | ORMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001176309 |
| CUSIP Number | 68403P203 |
| ISIN Number | US68403P2039 |
| Employer ID | 98-0376008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nadav Kidron Esq. | President, Chief Executive Officer and Executive Chairman |
| Joshua Hexter | Chief Operating and Business Officer |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer and Director |
| Avraham Gabay | Chief Financial Officer, Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 14, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 10-K | Annual Report |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13G/A | Filing |
| Jan 14, 2026 | 8-K | Current Report |
| Jan 7, 2026 | 8-K | Current Report |